|

STING MARK Universal Fiducial Marker System

RECRUITINGN/ASponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Actively Recruiting
PhaseN/A
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
Started2022-02-28
Est. completion2025-11-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05465161

Summary

Currently available fiducial marker and fiducial insertion strategies are rudimentary, imprecise, not compatible with multiple insertion catheters/needles and are overall unreliable. STING-MARK device is the first universal, fully detachable and non-premounted radiopaque fiducial device system. Allowing biopsy prior to insertion, STING-MARK is easily and reliably delivered through-the-needle to the tumor, in order to accurately pinpoint its location for image-guided therapies. This study aims at establishing proof of concept for STING-MARK, by demonstrating its usability, reproducibility, radio-opacity and retention in a variety of clinically-relevant ex vivo organ samples.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients undergoing surgical resection of solid organs
* Recipients of solid organ transplantation

Exclusion Criteria:

* None

Conditions1

Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.